High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 206-216

  Dent, Barry M ^a,b   Ogle, Laura F ^a   O'donnell, Rachel L ^a,c   Hayes, Nicholas ^b   Malik, Ujjal ^b   Curtin, Nicola J ^a   Boddy, Alan V ^a   Plummer, E Ruth ^a,b   Edmondson, Richard J ^a,c   Reeves, Helen L ^a,b   May, Felicity E B ^a   Jamieson, David ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

circulating tumour cells; hepatocellular carcinoma; ImageStreamX imaging flow cytometry; oesophageal adenocarcinoma; ovarian cancer; thyroid carcinoma

Indexed keywords

CD45 ANTIGEN; CELL ADHESION MOLECULE; CYTOKERATIN; SURVIVIN; MEMBRANE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CELL DAMAGE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMAGE QUALITY; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; VERY ELDERLY; IMMUNOPHENOTYPING; LIVER NEOPLASMS; METABOLISM; METASTASIS; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; THYROID NEOPLASMS; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; THYROID NEOPLASMS;

EID: 84944279875     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29680     Document Type: Article

References (49)

1. Ashworth A., A case of cancer in which cells similar to this in the tumours were seen in the blood after death. Aus Med J 1869; 146-9.
2. Cristofanilli M, Budd GT, Ellis MJ, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
3. de Bono JS, Scher HI, Montgomery RB, et al., Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9.
4. Krebs MG, Sloane R, Priest L, et al., Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556-63.
5. Allard WJ, Matera J, Miller MC, et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-904.
6. Tibbe AG, de Grooth BG, Greve J, et al., Optical tracking and detection of immunomagnetically selected and aligned cells. Nat Biotechnol 1999; 17: 1210-3.
7. Riethdorf S, Fritsche H, Muller V, et al., Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-8.
8. Talasaz AH, Powell AA, Huber DE, et al., Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106: 3970-5.
9. Stott SL, Hsu CH, Tsukrov DI, et al., Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010; 107: 18392-7.
10. Gleghorn JP, Pratt ED, Denning D, et al., Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a Chip 2010; 10: 27-9.
11. Nagrath S, Sequist LV, Maheswaran S, et al., Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
12. Maheswaran S, Sequist LV, Nagrath S, et al., Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-77.
13. Sequist LV, Nagrath S, Toner M, et al., The CTC-chip: An exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009; 4: 281-3.
14. Cristofanilli M, Hayes DF, Budd GT, et al., Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-30.
15. Budd GT, Cristofanilli M, Ellis MJ, et al., Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-9.
16. Hayes DF, Cristofanilli M, Budd GT, et al., Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-24.
17. Cohen SJ, Punt CJ, Iannotti N, et al., Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-9.
18. Olmos D, Arkenau HT, Ang JE, et al., Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 2009; 20: 27-33.
19. Tol J, Koopman M, Miller MC, et al., Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21: 1006-12.
20. Fehm T, Muller V, Aktas B, et al., HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-12.
21. Schoppmann SF, Jesch B, Zacherl J, et al., HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br J Surg 2011; 98: 1408-13.
22. Coumans FA, Doggen CJ, Attard G, et al., All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-7.
23. Pachmann K, Camara O, Kavallaris A, et al., Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26: 1208-15.
24. Kahn HJ, Presta A, Yang LY, et al., Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: Correlation with disease stage. Breast Cancer Res Treat 2004; 86: 237-47.
25. Krivacic RT, Ladanyi A, Curry DN, et al., A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004; 101: 10501-4.
26. Alix-Panabieres C, Brouillet JP, Fabbro M, et al., Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005; 299: 177-88.
27. Schwarzenbach H, Alix-Panabieres C, Muller I, et al., Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-8.
28. Hsieh HB, Marrinucci D, Bethel K, et al., High speed detection of circulating tumor cells. Biosensors & Bioelectronics 2006; 21: 1893-9.
29. Racila E, Euhus D, Weiss AJ, et al., Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998; 95: 4589-94.
30. Terstappen LW, Rao C, Gross S, et al., Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000; 17: 573-8.
31. Moreno JG, Miller MC, Gross S, et al., Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-8.
32. Hayes DF, Walker TM, Singh B, et al., Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-7.
33. Lara O, Tong XD, Zborowski M, et al., Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 2004; 32: 891-904.
34. Yang L, Lang JC, Balasubramanian P, et al., Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnology and Bioengineering 2009; 102: 521-34.
35. Tong X, Yang L, Lang JC, et al., Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytom B Clin Cytom 2007; 72B: 310-23.
36. Sieuwerts AM, Kraan J, Bolt J, et al., Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Instit 2009; 101: 61-6.
37. Trzpis M, McLaughlin PM, de Leij LM, et al., Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171: 386-95.
38. Lopez-Riquelme N, Minguela A, Villar-Permuy F, et al., Imaging cytometry for counting circulating tumor cells: Comparative analysis of the CellSearch vs.ImageStream systems. Apmis 2013; 121: 1139-43.
39. Hoffmann AC, Warnecke-Eberz U, Luebke T, et al., Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J. Surg Oncol 2007; 95: 51-4.
40. Sclafani F, Smyth E, Cunningham D, et al., A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. Clin Colorectal Cancer 2014; 13: 94-9.
41. Sato T, Harao M, Nakano S, et al., Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: Distinguishing follicular thyroid carcinoma from adenoma. Surgery 2005; 137: 552-8.
42. Schulze K, Gasch C, Staufer K, et al., Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013; 133: 2165-71.
43. Morris KL, Tugwood JD, Khoja L, Lancashire M, Sloane R, Burt D, Shenjere P, Zhou C, Hodgson C, Ohtomo T, Katoh A, Ishiguro T, Valle JW, Dive C, Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014; 74: 323-32.
44. Nel I, Baba HA, Ertle J, et al., Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013; 6: 420-8.
45. He W, Kularatne SA, Kalli KR, et al., Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer 2008; 123: 1968-73.
46. Marth C, Kisic J, Kaern J, et al., Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 2002; 94: 707-12.
47. Fan T, Zhao Q, Chen JJ, et al., Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009; 112: 185-91.
48. Ntouroupi TG, Ashraf SQ, McGregor SB, et al., Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008; 99: 789-95.
49. Obermayr E, Castillo-Tong DC, Pils D, et al., Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance-a study of the OVCAD consortium. Gynecol Oncol 2013; 128: 15-21.